Our corporate headquarters are in Santa Monica, California. If this describes you, please contact us. We realize that our ambitious goals can only be achieved if every employee is fully committed to our mission and embraces our entrepreneurial spirit. ![]() In all areas of the company, we are looking for the very best people who share our deep passion to cure cancer. With an unrelenting drive and a singular focus on cell therapy, our team is executing on our strategy to bring life-saving therapies to patients. Today, we are a leader in engineered T cell therapy, changing the paradigm of cancer treatment with what is potentially the biggest breakthrough since the introduction of combination chemotherapy more than 60 years ago. This mission is at the heart of everything we do, from early research to product development.įor the past three decades, members of our team have been at the forefront of cancer immunotherapy. The company contracts with third-party manufacturers for certain active pharmaceutical ingredients (APIs) and commercial products.Kite, a Gilead company, is dedicated to achieving one of the most ambitious goals of 21st century medicine: curing cancer. Kite Pharma’s clinical and commercial manufacturing facilities are in Foster City, San Dimas, La Verne, El Segundo, and Oceanside in California Cork, Ireland and Edmonton, Canada. More than 700 Kite employees became part of Gilead’s portfolio following the acquisition. Marketing commentary on Kite Pharmaīased in Santa Monica, California, US, Kite Pharma is a pharmaceutical company focused on the development and manufacture of immune-based cell therapies for cancer treatment, with its manufacturing operations in North America and Europe.īiotechnology company Gilead Sciences acquired Kite Pharma for $11.9bn in October 2017. More than 10,000 patients have been treated with Kite’s CAR T-cell therapies worldwide. A viral vector is then used to encode a CAR in the T-cells to enable them to recognise and attack cancer cells in the patient. The manufacturing of CAR T-cell therapies involves the removal of T-cells from a patient’s blood. TCRs are specifically modified proteins for a particular type of cancer, which enables T-cells to recognise and kill antigens expressed by the tumour cells. CAR T-cell therapies are one-time treatments produced from a patient’s white blood cells or T-cells.ĬARs are engineered proteins that contain an antibody or target-binding component to identify the specific antigen expressed by the tumour cells and other signal-activating components for T-cells to kill tumour cells. Kite Pharma develops T-cell-based cancer immunotherapies for oncology by using a chimeric antigen receptor (CAR) or a T-cell receptor (TCR), based on the type of cancer. It also supports the production of KITE-718 therapy. The facility develops a replication-deficient lentiviral vector, which is used to produce an investigational biologic candidate KITE-585. Kite and Shoreline Biosciences Enter Into Strategic Partnership to Develop Novel Allogeneic Cell Therapies. The retroviral vector PG13-CD19-H3 is also used for the development of other investigational therapy candidates such as KTE-X19 for acute lymphocytic leukaemia and mantle cell lymphoma. T-cells from the WBCs are extracted, modified and re-infused into the patients to identify and kill cancer cells. Yescarta is developed from the patient’s own white blood cells (WBCs). It was the company’s first CAR T-cell therapy that was approved by the FDA in 2017 and is used for the treatment of large B-cell lymphoma in adult patients. PG13-CD19-H3 is the important starting material used to produce Yescarta. The new facility is dedicated to the manufacture of viral vectors such as replication-deficient gamma-retroviral vector PG13-CD19-H3 and replication-deficient lentiviral vector. The facility is staffed by a team of experts and operates under stringent regulatory guidelines to ensure that the finished products are safe, pure, and effective. The state-of-the-art viral vector manufacturing facility is a 100,000ft² building focused on the development and production of viral vectors in-house for pre-clinical or early-stage clinical trials, as well as commercial use. Kite Pharma’s viral vector manufacturing facility details In March 2022, Gilead purchased approximately 27 acres of land in Oceanside, next to the existing facility to support future manufacturing operations. ![]() Oceanside can be accessed through three highways, I-5, Highway 78, and Highway 76. Situated between Los Angeles and San Diego, Oceanside is connected to Los Angeles by Interstate I-405 South and to San Diego by Interstate I-5 North. The facility was purchased from Genentech in August 2011. The viral vector manufacturing facility is located within Gilead’s existing biologics operation facility at 4049 Avenida de la Plata, Oceanside. Location of the viral vector manufacturing facility
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |